{
    "Trade/Device Name(s)": [
        "ADVIA Centaur Intact Parathyroid Hormone (iPTH) Assay",
        "ADVIA Centaur Intact PTH Assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K133601",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121981"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEW"
    ],
    "Summary Letter Date": "December 30, 2013",
    "Summary Letter Received Date": "December 31, 2013",
    "Submission Date": "February 4, 2014",
    "Regulation Number(s)": [
        "21CFR862.1545"
    ],
    "Regulation Name(s)": [
        "Parathyroid hormone test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Intact Parathyroid Hormone (iPTH)"
    ],
    "Specimen Type(s)": [
        "EDTA plasma",
        "Serum"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur",
        "ADVIA Centaur XP"
    ],
    "Method(s)/Technology(ies)": [
        "Two-site sandwich immunoassay",
        "Chemiluminometric technology"
    ],
    "Methodologies": [
        "Immunoassay",
        "Chemiluminescence"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit",
        "Calibrator",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur Intact Parathyroid Hormone (iPTH) Assay using two-site sandwich immunoassay and chemiluminometric technology for quantitation of iPTH in EDTA plasma or serum.",
    "Indications for Use Summary": "For in vitro diagnostic quantitative determination of intact parathyroid hormone (iPTH) in EDTA plasma or serum to aid in the differential diagnosis of hyperparathyroidism and hypoparathyroidism.",
    "fda_folder": "Clinical Chemistry"
}